1. Home
  2. CCK vs DVA Comparison

CCK vs DVA Comparison

Compare CCK & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crown Holdings Inc.

CCK

Crown Holdings Inc.

HOLD

Current Price

$107.19

Market Cap

11.5B

Sector

Industrials

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$149.94

Market Cap

10.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCK
DVA
Founded
1906
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Misc Health and Biotechnology Services
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5B
10.0B
IPO Year
2003
2002

Fundamental Metrics

Financial Performance
Metric
CCK
DVA
Price
$107.19
$149.94
Analyst Decision
Strong Buy
Hold
Analyst Count
16
4
Target Price
$122.75
$156.75
AVG Volume (30 Days)
873.5K
724.0K
Earning Date
04-27-2026
05-11-2026
Dividend Yield
0.96%
N/A
EPS Growth
79.72
N/A
EPS
6.38
9.84
Revenue
$11,665,000,000.00
$13,643,069,000.00
Revenue This Year
$4.97
$3.85
Revenue Next Year
$2.39
$3.07
P/E Ratio
$16.92
$15.32
Revenue Growth
N/A
6.46
52 Week Low
$83.23
$101.00
52 Week High
$116.62
$159.42

Technical Indicators

Market Signals
Indicator
CCK
DVA
Relative Strength Index (RSI) 55.33 50.72
Support Level $98.41 $146.05
Resistance Level $107.71 $152.31
Average True Range (ATR) 2.70 3.54
MACD 0.98 -0.85
Stochastic Oscillator 83.05 42.07

Price Performance

Historical Comparison
CCK
DVA

About CCK Crown Holdings Inc.

Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Share on Social Networks: